TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04852315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
Study: NCT01894074

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Dietary Intervention
Description: Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
Study: NCT02425969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
Study: NCT02728206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT02194452

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gallium Ga 68-edotreotide
Description: Undergo gallium Ga 68-edotreotide PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00617162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation, Libra Deep Brain Stimulation System
Description: DBS Active Treatment Group - implanted with investigational device and activated for stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Deep Brain Stimulation, Libra Deep Brain Stimulation System
Description: implanted with investigational device, but will not receive active stimulation for the first 6 months of the study
Study: NCT01955785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Regulated Volume Controlled Ventilator
Study: NCT01633528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asprin
Description: 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg
Study: NCT03908931

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Follow up of osteochondral surgery by MRI and clinical examination
Study: NCT03209986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell transplantation via peripheral vein
Description: 1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
Study: NCT03151811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study: NCT01888679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head movement
Description: Head movement in extension, flexion, right and left rotation
Study: NCT04023851

Intervention type: DEVICE
Intervention: Mobile application Brain4U
Description: Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.

Intervention type: DEVICE
Intervention: Mobile application Brain4U
Description: Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
Study: NCT00840450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec/Paclitaxel
Description: One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression.
Study: NCT03841669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group
Description: Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity & Health Information Group
Description: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
Study: NCT02495168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Budesonide/Formoterol Fumarate Dihydrate
Description: Oral inhalation, generic formulation of the brand-name product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)
Description: Oral inhalation, brand-name product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation, no active ingredient.
Study: NCT03254836

Intervention type: OTHER
Intervention: Standard of care
Description: Elective radical surgery for adenocarcinoma.
Study: NCT02442518

Intervention type: PROCEDURE
Intervention: antenatal ultrasound
Description: Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
Study: NCT04293120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with weighted ball
Description: Participants will stop or catch a weighted ball
Study: NCT01603056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pangramin SLIT HDM mix.
Description: Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
Study: NCT01484847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
Study: NCT02853604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02688205

Intervention type: OTHER
Intervention: Cyriax's functional examination
Description: included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation

Intervention type: OTHER
Intervention: Cyriax's functional examination
Description: included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation

Intervention type: DEVICE
Intervention: Ultrasound examination
Description: to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa

Intervention type: DEVICE
Intervention: Ultrasound examination
Description: to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
Study: NCT01482000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary daoyin therapy of China
Description: The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
Study: NCT03209986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
Study: NCT02448797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) orally for two years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
Study: NCT04469257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sunbathing
Description: the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
Study: NCT03577522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avenir cementless hip stem
Description: Avenir cementless hip stem vs Corail HA-coated hip stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail HA-coated hip stem
Description: Avenir cementless hip stem vs Corail HA-coated hip stem
Study: NCT01997138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg in 2 ml saline IA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra 100 mg in 2 ml saline IA
Study: NCT01482000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The control group will get the usual care with some additional tests for the study.
Study: NCT03047694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tablet therapy
Description: stimulation of the lexico semantic system on a tactile tablet therapy for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: speech therapy
Study: NCT01129817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy and exercise
Description: Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
Study: NCT03434275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study: NCT01701856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Description: 250 mcg, s.c., each other day for 12 months
Study: NCT01081834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 26 weeks (Main Study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
Study: NCT01161407

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1500 mg/d elemental calcium as calcium carbonate
Description: 500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
Study: NCT02377050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Volume Feeding Goal
Description: feeding volume goal of 180-200 ml/kg/day
Study: NCT03256279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: .014 NiTi heat-activated archwire
Description: .014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .014 NiTi Superelastic archwire
Description: .014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment
Study: NCT03294902

Intervention type: DEVICE
Intervention: Pedra Tissue Perfusion Monitor
Description: This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.

Intervention type: DEVICE
Intervention: Pedra Tissue Perfusion Monitor
Description: This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.

Intervention type: DEVICE
Intervention: Pedra Tissue Perfusion Monitor
Description: This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
Study: NCT03645369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
Study: NCT01274676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid stenting with MOMA
Description: The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting with filter wire EZ
Description: The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
Study: NCT03645369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Ice pack containing gel
Study: NCT02487602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis100
Description: Gelesis100 capsules

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis100
Description: Gelesis100 capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Gelesis100 capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Gelesis100 capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sucrose (sugar) capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sucrose (sugar) capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose (sugar) capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose (sugar) capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose (sugar) capsules
Study: NCT01780818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
Study: NCT02732119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
Study: NCT01894074

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day